Literature DB >> 19635959

In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus.

Shveta Rani Singh1, Alfred E Bacon, David C Young, Kimberly A Couch.   

Abstract

Many clinicians are trying unique strategies, including vancomycin and linezolid in combination, for treatment of patients who do not respond to conventional therapy against methicillin (meticillin)-resistant Staphylococcus aureus. In our study, which illustrated in vitro activity only, no synergistic activity was seen when the two agents were combined. Conversely, antagonistic activity occurred in three of five strains when linezolid was added to vancomycin. Our results indicate that vancomycin and linezolid in combination should be avoided.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19635959      PMCID: PMC2764166          DOI: 10.1128/AAC.00237-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Increase in community-acquired methicillin-resistant Staphylococcus aureus at a Naval Medical Center.

Authors:  A J Kallen; T J Driscoll; S Thornton; P E Olson; M R Wallace
Journal:  Infect Control Hosp Epidemiol       Date:  2000-03       Impact factor: 3.254

2.  In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.

Authors:  Michael T Sweeney; Gary E Zurenko
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

3.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

Authors: 
Journal:  Am J Infect Control       Date:  2004-12       Impact factor: 2.918

4.  Survey of long-term-care facilities in Iowa for policies and practices regarding residents with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci.

Authors:  Trisha Kreman; Jianfang Hu; Jean Pottinger; Loreen A Herwaldt
Journal:  Infect Control Hosp Epidemiol       Date:  2005-10       Impact factor: 3.254

5.  Linezolid eradicates MRSA better than vancomycin from surgical-site infections.

Authors:  John Weigelt; Haytham M A Kaafarani; Kamal M F Itani; Robert N Swanson
Journal:  Am J Surg       Date:  2004-12       Impact factor: 2.565

6.  Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  Fu-Yu Chiang; Michael Climo
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

7.  Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.

Authors:  Richard G Wunderink; Jordi Rello; Sue K Cammarata; Rodney V Croos-Dabrera; Marin H Kollef
Journal:  Chest       Date:  2003-11       Impact factor: 9.410

8.  Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania.

Authors:  Fred C Tenover; Linda M Weigel; Peter C Appelbaum; Linda K McDougal; Jasmine Chaitram; Sigrid McAllister; Nancye Clark; George Killgore; Caroline M O'Hara; Laura Jevitt; Jean B Patel; Bülent Bozdogan
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

9.  In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods.

Authors:  Cedric Jacqueline; Jocelyne Caillon; Virginie Le Mabecque; Anne-Francoise Miegeville; Pierre-Yves Donnio; Denis Bugnon; Gilles Potel
Journal:  J Antimicrob Chemother       Date:  2003-03-13       Impact factor: 5.790

10.  Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates.

Authors:  Jaime G Deville; Stuart Adler; Parvin H Azimi; Barbara A Jantausch; Maria Rayo Morfin; Sandra Beltran; Barbara Edge-Padbury; Sharon Naberhuis-Stehouwer; Jon B Bruss
Journal:  Pediatr Infect Dis J       Date:  2003-09       Impact factor: 2.129

View more
  11 in total

1.  Discovery and characterization of potent thiazoles versus methicillin- and vancomycin-resistant Staphylococcus aureus.

Authors:  Haroon Mohammad; Abdelrahman S Mayhoub; Adil Ghafoor; Muhammad Soofi; Ruba A Alajlouni; Mark Cushman; Mohamed N Seleem
Journal:  J Med Chem       Date:  2014-01-14       Impact factor: 7.446

2.  The use of bone cement for the localized, controlled release of the antibiotics vancomycin, linezolid, or fusidic acid: effect of additives on drug release rates and mechanical strength.

Authors:  John Jackson; Fay Leung; Clive Duncan; Clement Mugabe; Helen Burt
Journal:  Drug Deliv Transl Res       Date:  2011-04       Impact factor: 4.617

3.  Structural optimization and antibacterial evaluation of rhodomyrtosone B analogues against MRSA strains.

Authors:  Liyun Zhao; Hongxin Liu; Luqiong Huo; Miaomiao Wang; Bao Yang; Weimin Zhang; Zhifang Xu; Haibo Tan; Sheng-Xiang Qiu
Journal:  Medchemcomm       Date:  2018-09-07       Impact factor: 3.597

4.  Observed Antagonistic Effect of Linezolid on Daptomycin or Vancomycin Activity against Biofilm-Forming Methicillin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Model.

Authors:  Megan K Luther; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

5.  Combination Antibiotic Exposure Selectively Alters the Development of Vancomycin Intermediate Resistance in Staphylococcus aureus.

Authors:  Xuting Zheng; Andrew D Berti; Sue McCrone; Melanie Roch; Adriana E Rosato; Warren E Rose; Baiyi Chen
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

6.  Antagonistic Effect of Colistin on Vancomycin Activity against Methicillin-Resistant Staphylococcus aureus in In Vitro and In Vivo Studies.

Authors:  Sungim Choi; Song Mi Moon; Su-Jin Park; Seung Cheol Lee; Kyung Hwa Jung; Heung-Sup Sung; Mi-Na Kim; Jiwon Jung; Min Jae Kim; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jin-Yong Jeong; Jun Hee Woo; Yang Soo Kim; Yong Pil Chong
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

7.  Novel pyrazoles as potent growth inhibitors of staphylococci, enterococci and Acinetobacter baumannii bacteria.

Authors:  Ibrahim Alkhaibari; Hansa Raj Kc; Duminduni H Angappulige; David Gilmore; Mohammad A Alam
Journal:  Future Med Chem       Date:  2021-12-08       Impact factor: 3.808

8.  Ramoplanin at bactericidal concentrations induces bacterial membrane depolarization in Staphylococcus aureus.

Authors:  Mu Cheng; Johnny X Huang; Soumya Ramu; Mark S Butler; Matthew A Cooper
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

9.  Translational Pharmacometric Evaluation of Typical Antibiotic Broad-Spectrum Combination Therapies Against Staphylococcus Aureus Exploiting In Vitro Information.

Authors:  S G Wicha; W Huisinga; C Kloft
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-07-13

10.  In Vitro Antibacterial Activity of Rhodanine Derivatives against Pathogenic Clinical Isolates.

Authors:  Ahmed AbdelKhalek; Charles R Ashby; Bhargav A Patel; Tanaji T Talele; Mohamed N Seleem
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.